Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02747888 · ClinicalTrials.gov registry record · NA
Hereditary Risk Factors for Thyroid Cancer
A NA study of Thyroid Cancer, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 250
- Enrollment target
- 1
- Study location
NCT02747888: Recruiting NA study of Thyroid Cancer, sponsored by Dana-Farber Cancer Institute.
NCT02747888 is a NA study of Thyroid Cancer that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 250 participants, roughly in line with the 276-participant average among 46 other Thyroid Cancer trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02747888, a NA study of Thyroid Cancer, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
Thyroid cancers can occur sporadically, but can also be found as tumors that cluster in families with other cancers or genetic syndromes. Researchers are studying thyroid cancer in children and families, with a particular interest in understanding genes and other factors that may put individuals at risk for developing thyroid cancer and thyroid nodules. * In this study, family and medical history information is collected alongside a blood or saliva sample for genetic studies. * Individuals with a past or present childhood thyroid cancer/nodule or a thyroid cancer suspected to be inherited in their family are invited to participate.
Conditions Studied
Interventions
- GENETIC •Referral to Genetic Counselor, if indicated
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2016-03-01 |
| Est. Completion | 2029-03-01 |
| Phase | NA |
What NCT02747888 shows while recruiting
NCT02747888 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 276-participant average among 46 other Thyroid Cancer trials with a reported enrollment target.
The record links to 1 condition, with Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which •Referral to Genetic Counselor, if indicated is the first listed.
NCT02747888 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02747888 about?
NCT02747888 is a clinical study titled "Hereditary Risk Factors for Thyroid Cancer". Thyroid cancers can occur sporadically, but can also be found as tumors that cluster in families with other cancers or genetic syndromes. Researchers are studying thyroid cancer in children and families, with a particular interest in understanding genes and other factors that may put individuals at ...
What is the current status of trial NCT02747888?
This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2016-03-01. Estimated completion is 2029-03-01.
What conditions does trial NCT02747888 study?
This clinical trial studies the following conditions: Thyroid Cancer.
What interventions are being tested in trial NCT02747888?
The interventions under investigation include: •Referral to Genetic Counselor, if indicated (GENETIC).
Who is sponsoring clinical trial NCT02747888?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02747888 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02747888's enrollment target sits among peer trials
250 11th of 46 higher than 36 of 46 other Thyroid Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
TRAIL Study: Feasibility and Pilot
RECRUITING · NA
-
Personalized Treatment in Thyroid Disorders
RECRUITING · NA
-
Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer
RECRUITING · NA
-
Assessing Patient Satisfaction and Confidence After Use of Educational Video to Augment Surgical Consent for Thyroid Surgery
RECRUITING · NA
-
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI